72.11.Z - Scientific research and development activities
46.46.Z - Wholesale trade of pharmaceutical and medical products
46.75.Z - Wholesale trade
47.73.Z - Retail sale of pharmaceutical products
71.20.B - Inspection and issuing opinions on the technical condition of chimneys and ventilation ducts
72.19.Z - Scientific research and development activities
73.12.B - Advertising through mass media
73.12.D - Advertising through mass media
82.30.Z - Activities related to organizing fairs, exhibitions, and congresses
85.59.B - Courses and training for acquiring knowledge, skills, and professional qualifications in non-school forms
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | 11,2 | 13,8 | 20,3 | 47,3 |
EBITDA | 12,2 | 14,7 | 20,7 | 40,1 |
Short time liabilities | 36,9 | 46,4 | 63,5 | 36,9 |
Equity capital | 31,8 | 41,5 | 56,4 | 35,9 |
Operating profit (EBIT) | 11,8 | 14,3 | 20,2 | 41,3 |
Assets | 79,9 | 102,2 | 150,6 | 47,4 |
Net profit (loss) | 11,9 | 9,7 | 14,9 | 54,1 |
Cash | 7,8 | 1,1 | 8,9 | 730,1 |
Net income from sale | 169,1 | 234,2 | 327,1 | 39,7 |
Liabilities and provisions for liabilities | 48,1 | 60,7 | 94,2 | 55,3 |
Working assets | 71,4 | 93,1 | 136,4 | 46,5 |
Depreciation | 0,4 | 0,4 | 0,5 | 3,3 |
% | % | % | p.p. | |
Profitability of capital | 37,3 | 23,3 | 26,4 | 3,1 |
Equity capital to total assets | 39,8 | 40,6 | 37,4 | -3,2 |
Gross profit margin | 6,6 | 5,9 | 6,2 | 0,3 |
EBITDA Margin | 7,2 | 6,3 | 6,3 | 0 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 80 | 72 | 71 | -1 |
Current financial liquidity indicator | 1.5916368961334229 | 1.609873652458191 | 1.5807162523269653 | 0 |
Net dept to EBITDA | -0.634123682975769 | 0.08203549683094025 | -0.4310552179813385 | -0,5 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane